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1. IntroductIon
There is an urgent need for the development of radiation 
countermeasure agents to ameliorate or reduce the morbidity 
and mortality caused due to radiation over exposures in 
planned and unplanned activities1. Protection of biological 
systems against ionising radiation is of paramount importance 
during planned exposure to radiation. Despite the great 
efforts and investment, we are far away from a potent radio 
protector suitable for human application. Radioprotectors are 
agents which need to be present in the body during the time 
of irradiation, in order to protect the exposed individual. They 
need to have antioxidant activity predominantly so that free 
radicals generated from interaction of biological system which 
is rich in water with irradiation are scavenged and cells are 
protected. 
Agents used to modify radiation induced alterations 
are classified into three broad categories based on their time 
of delivery and mode of action as protectors, mitigators and 
therapeutics. Radioprotectors are given prior to radiation 
exposure; hence they are helpful in planned radiation exposure 
like as in radiotherapy and first responder applications. 
This group includes a wide range of herbal and synthetic 
compounds different mechanism of action and structure of 
the active constituent(s). The aminothiol amifostin is the only 
radioprotectant approved for human application in clinical 
scenarios2. Amifostin detoxifies the reactive metabolites of 
alkylating agents as well as scavenges free radicals so as to 
render radioprotective action, other possible mechanisms 
of its radioprotective action include DNA repair, inhibition 
of apoptosis, alteration in gene expression and modification 
of various enzyme activity3,4, etc. Despite being a potent 
radioprotector, its application is limited due to toxicity 
concerns as it has potential to cause hypotension, neurotoxicity, 
etc. There are many herbal compounds which have shown 
antioxidant activity and can prove to be a radioprotector with 
no apparent toxicity. They can scavenge reactive oxygen 
and nitrogen species (ROS and RNS) from the cells and 
protect them from adverse effects of ionising radiation. Plant 
metabolites like: alkaloids, flavonoids lycopene, peptides, 
polysaccharides, phytohormones extracted from herbs like 
Allium sativum, Camellia sinensis, Hippophae rhamnoides, 
Tinospora cordifolia, Ocimum sanctum, Emblica officinalis 
are some of the examples. 
Mitigators are the radiation countermeasure agents that 
are administered shortly after or during radiation exposure but 
prior to the manifestation of symptoms of radiation exposure. 
They act predominantly through the repair of the damages 
and inflammation caused due to radiation exposure. Therefore 
being antioxidant or free radical scavenger is not a prerequisite 
for such agents unlike radioprotectors. Many cytokines and 
growth factors have been reported as radiomitigator. These 
agents stimulate differentiation of various stem cells in bone 
marrow and intestine thereby mitigates death by hematopoietic 
syndrome and GI syndrome by replenishing the damaged cells 
with new and healthy ones. 
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Therapeutic drugs are those given after the appearance 
of symptoms of radiation exposure and they act to ameliorate 
tissue toxicity and enhance tissue repair. Figure 1 gives a 
diagrammatic presentation of different classes of radiation 
countermeasure agents and their properties. Examples of 
currently available agents in each class are depicted in Table 1.
conversion to wR 1065 by dephosphorylation via cellular 
alkaline phospahatase9. The selective protection of normal 
tissue is the result of greater accumulation of wR 1065 in 
the non tumor cells than in tumor cells. Tumors are relatively 
hypovascular thus resulting in relative hypoxia and a low 
interstitial pH. Moreover, alkaline phospahatase expression is 
reduced in malignant tissues. So the combination of hypoxia, 
acidic pH and low expression of alkaline phospahatase results 
in less accumulation of active compound in the tissue10. wR 
2721 shows many adverse effects such as nausea, vomiting, 
hypotension, sneezing, somnolence, a metallic taste during 
infusion and occasionally allergic reaction that may include 
rash, fever and anaphylactic shock11,12 limiting its application. 
Administration of amifostin shows protection to normal cells 
in the head and neck cancer, ovarian carcinoma, myeloid 
leukemia when it is dependent on p53 patients against oral 
mucositis, pneumonitis, esophagitis, and dermatitis13,14.
2.2 G-cSF/neupogen/Filgrastim
Other than amifostin a number of compounds are at 
different stages of development as radioprotectors. Granulocyte-
Colony Stimulating Factor (G-CSF) and Granulocyte-
Monocyte-Colony Stimulating Factor (GM-CSF) are likely 
to receive FDA approval15 in near future. G-CSF provides 
protection against radiation induced hematopoietic as well as 
gastrointestinal injuries and testicular dysfunction16-17. G-CSF 
is a cytokine produced by monocyte, fibroblast and endothelial 
cells which stimulates the proliferation, differentiation and 
enhances phagocytic activity of neutrophils in the bone 
marrow and protect against radiation induced neutropenia18. 
It acts by binding to its transmembrane receptor Granulocyte 
Colony Stimulating Factor Receptor (GCSF-R) which is a 
class-1 cytokine receptor family member present on various 
hematopoietic cells such as multipotent stem cells, Granulocyte-
Monocyte progenitor cells and lymphoid progenitor cells. 
G-CSF with its receptor forms homo-oligomeric receptor 
complex. A signal cascade is activated by phosphorylating 
JAK-2 leading to JAK-STAT pathway activation, ras/raf/erk 
pathway activation, and anti-apoptotic pathway activation. 
G-CSF stimulate different progenitor cells such as lymphoid 
progenitor, erythroid progenitor, basophil progenitor and 
eosinophil progenitors which further give rise to lymphocyte, 
erythrocyte, basophils, respectively18. The efficacy of G-CSF 
has been evaluated in mice, canines (beagle), NHPs and mini 
pigs15. Survivability and radioprotection has been improved by 
G-CSF across species18,19.
Neupogen (recombinant methonyl human G-CSF) is 
a recombinant derivatives of G-CSF produced in E. coli 
expression system. It differs from G-CSF in having an 
N-terminal methionine tail for the expression in a prokaryotic 
system furthermore it is non-glycosylated. Neulasta is a 
pegylated version of G-CSF. It is a covalent conjugate of 
human G-CSF. Administration of only two doses of Neulasta 
has been shown to be more effective against radiation induced 
neutropenia compared to daily dose of neupogen. 
GM-CSF is also a colony stimulating factor and has been 
evaluated across species (mice, canine and NHPs). Unlike 
G-CSF, it is species specific and survival benefits are also 
Figure 1. chart showing different radiation countermeasure 
classification and their properties.
Acute radiation syndrome (ARS) occurs in human 
following exposure to higher than 1 Gy of whole body radiation 
or relatively significant dose of partial body irradiation delivered 
at a high dose rate. Hematopoietic ARS occurs at a dose 
range of 2 Gy - 6 Gy, Gastrointestinal (GI) at 6Gy - 8 Gy and 
Cerebrovascular at still higher dose >8 Gy5. Cerebrovascular 
syndrome is almost irremediable since it leads to death almost 
immediately. Thus hematopoietic and GI syndromes are 
specific targets for the development of radiation countermeasure 
agents. The hematopoietic syndrome is characterised by an 
immense loss of hematopoietic stem cells (HSCs) which 
are highly radiosensitive primarily owing to their active 
proliferation. The GI syndrome is characterised by massive 
cell death or apoptosis in epithelial cells followed by disruption 
of intestinal crypt cells. Diminished food intake and water 
absorption, electrolyte imbalance, intestinal bleeding and sepsis 
as a result of exposure to GI doses lead to death eventually6.
2. rAdIoProtEctorS
Many synthetic, semisynthetic and natural compounds 
have been evaluated on different biological system as 
radioprotectors. Free radical scavengers, compounds capable 
of inducing delay in cell division, induction of hypoxia, and 
donation of hydrogen atom to the radical are some important 
properties of those compounds investigated as radioprotectors. 
Various plant extracts with above properties have been 
evaluated for their radioprotection ability but none of them 
have reached clinics so far despite having low toxicity7. 
2.1 Amifostin 
Amifostin (wR 2721), a thiol, is a potent radioprotector 
that has been approved by USFDA for human application but 
only under strict medical supervision. It can scavenge oxygen 
derived free radicals and is applied in the head and neck 
cancer patients undergoing radiotherapy to protect the non 
tumor tissues8. Amifostin is a pro-drug that is inactive until 
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S. no name test system uses optimum doses drF ref.
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1  wR2721 Sprague-Dawley 
(SD) rats
Scavenge oxygen derived free radicals to 
protect non-tumor tissues
200 mg/kg NA 8 - 14
2 Filgrastim BALB/c, C3H/
HeNCr mice
Protection against radiation induced 
hematopoietic as well as gastrointestinal 
injuries and testicular dysfunction 
NIH BALB/c: 2,000 ug/
kg; CR BALB/c: 1 ug/kg; 
C3H mice: 200 ug/kg.
NA 15, 16, 
18-19,
3 γ-tocotrienol Nonhuman 
Primates, CD2F1 
strain mice
To reduce the mortality rate caused due to 
radiation induced hematopoietic syndrome 
75 mg/kg 1.29 21-27
4 Genistein BALB/c mice Scavenge free radicals and reduce the 
oxidative stress generated by radiation 
ultimately ameliorating DNA damage
200 mg/kg NA 28-31, 
33
5 Herbal Radioprotectors
i Podophyllum 
hexandrum
Strain ‘A’ Swiss 
Albino mice
Precursor of topoisomerase inhibitor 200 mg/Kg 1.33 35
ii Hippophae 
rhamnoides
Strain ‘A’ Swiss 
Albino mice
Diminish damage in DNA, scavenge free 
radicals, ameliorate chromosomal aberration 
in bone marrow cells and protection against 
hematopoietic syndrome
30 mg/kg NA 36, 37
iii Ocimum sanctum  B16F1 melanoma 
and Fibrosarcoma 
bearing mice
Antioxidant activity, protect against lipid 
peroxidation in liver, ability to scavenge 
the free radicals, metal chelating and anti-
inflammatory activity which provide protection 
to normal tissue against radiation
10 mg/kg/day for five 
consecutive days
1.28 40
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1 5-androstenediol CD2F1 mice, 
C3H/HeN mice, 
C3H/FeJ
Recovery of various bone marrow lineages 
against radiation induced myelosuppression 
10 mg/kg, 30 mg/kg, and 
100 mg/kg
1.25 47 - 49
2 Histone 
Deacetylase 
inhibitors
BALB/c mice Increase histone acetylation thus increasing 
the accessibility of repair proteins to DNA and 
enhancing DNA repair
0 h (TSA 0.5 mg/kg; VPA 
600 mg/kg); 5 h (TSA, 0.5 
mg/kg; VPA, 300 mg/kg)
NA 52, 53
3 Sulforaphane whole blood 
culture
Ameliorate radiation induced micronuclei 
frequency in human lymphocytes
400 nM NA 52,54
4 Diallyl Sulphide Rats, C57 Bl/6 
mice
Enhances the bone marrow cellularity and 
spleen colony forming unit which further 
enhances the lymphocyte count
200 mg/kg NA 55,56
5 Epigallocatechin-
3-gallate
C57 Bl/6 mice Protection against radiation induced DNA 
break, DNA damage and lipid peroxidation 
and membrane fluidity and reduction in 
frequency of apoptosis in crypt cells 
0.1833 mg/kg NA 46
NA=not available
table 1. current status of various radiation countermeasure agents
inconsistent. Like G-CSF, GM-CSF also recovers the total 
blood count, neutrophil count and leukocyte count decreased 
due to radiation. Compared to GM-CSF, G-CSF shows 
more protection from hematopoietic injuries and it is more 
effective20.
2.3 γ-tocotrienol
After promising radioprotective activity of GT3 (member 
of vitamin E family) in the rodents, its efficacy in non-human 
primates (NHP) model is under evaluation. It reduces the 
mortality rate caused due to radiation induced hematopoietic 
syndrome by recovery in neutropenia and thrombocytopenia 
and is also found effective against GI syndrome. Compared 
to multiple doses of Neupogen and neulasta, GT3 is effective 
in a single dose without any supportive care in NHP 21. The 
precise mechanism of radioprotection by GT3 is not well 
known but it provides protection against radiation by up-
regulating the expression of G-CSF, interleukin IL-1α, IL-1β, 
IL-6, IL-17, macrophage inflammatory protein within 24 h of 
administration of the drug22,23. It also shows protection by up 
regulation of A20, the inhibitor of NF-κB in case there is basal 
level of expression of NF-κB, up regulation of anti-apoptotic 
genes and down regulation of pro-apoptotic genes bak-1 both 
at the transcriptional and translational level in the intestine24,25. 
GT3 protects normal tissues from hematopoietic and GI 
injuries by protecting hematopoietic stem and progenitor cells 
and epithelial crypt cells of intestine from the DNA damage 
caused by ionising radiation26,27.
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2.4 Genistein 
Genistein, a phytoestrogen, has antioxidant activity and 
it also inhibits protein tyrosine kinase that modulate signal 
transduction pathway. when administered before irradiation it 
provides protection against intestinal damage, lung injury, and 
acute hematopoietic syndrome28-31. Genistein scavenges free 
radicals and reduces the oxidative stress generated by radiation 
ultimately ameliorating DNA damage. Hematopoietic cells are 
recovered due to enhanced activity of IL-6 and G-CSF level and 
suppression of TNF-α mediated inflammation through inhibition 
of ROS/Akt/NF-κB pathway by administration of genistein 
24 h prior to radiation exposure. Nanoparticle formulation of 
genistein shows protection from apoptosis in hematopoietic 
stem and progenitor cells against radiation and increased bone 
marrow cellularity that promotes hematopoiesis32,33.
 
2.5 Herbal radioprotector
Various herbal products have been evaluated as 
radioprotector because of their anticipated low toxicity 
and excellent antioxidant activity. These include medicinal 
plants, green vegetables, fruits, ornamental plants and spices. 
Plant extracts can be good radioprotector because they are 
rich in compounds such as alkaloids, flavonoids, peptides, 
polysaccharides, vitamin B, C, E and β-carotene displaying 
antioxidant, anti-microbial and anti-inflammatory activities. 
Despite having several properties of ideal radioprotectors, 
there are some drawbacks with development of herbal 
products34 like extraction method, batch to batch variation, 
seasonal variation, etc.
2.5.1 Podophyllum Hexandrum
The herbal extract of P. haxandrum shows 80 per cent 
of radioprotection. It contains podophyllotoxin and other 
bioactive constituents which is a cure for many inflammatory 
and allergic conditions of the skin, cold, constipation, skin, 
bladder, lungs and brain cancer. In the treatment of leukemia, 
lung and testicular cancer, psoriasis, malaria, rheumatoid 
arthritis podophyllotoxin has been used as a precursor of 
topoisomerase inhibitor. In the last couple of decades many 
radioprotective studies using P. hexandrum has been performed 
such as survival studies, gastroprotection, neuroprotection, 
hepatoprotection, hematopoietic system protection in different 
strain of mice against gamma radiation35.
2.5.2 Hippophae Rhamnoides
It belongs to the Elaegnaceae family and it has been 
reported that its alcohol and aqueous extracts render increased 
survivability (up to 82 per cent). Both the extracts of H. 
rhamnoides diminish damage in DNA, scavenge free radicals, 
ameliorate chromosomal aberration in bone marrow cells and 
thus provide protection against hematopoietic syndrome. On the 
parameters of toxicity study the leaf extract of H. rhamnoides 
was found less toxic than the berry extract. Both the extracts 
are promising radioprotector in vivo but further studies are 
required before it can reach clinical set up36,37.
2.5.3 Ocimum Sanctum
It belongs to the lamiaceae family containing two 
flavonoids orientin (Ot) and vicenin (Vc) in the leaves. Both 
flavonoids have been evaluated against radiation induced 
chromosomal aberration in mice. They have been observed to 
reduce micronuclei frequency in bone marrow and peripheral 
blood cells as well. Both compound show antioxidant activity 
against radiation and protect against radiation induced lipid 
peroxidation in liver. Both compounds have the ability to 
scavenge the radiation induced free radicals38,39. They also show 
metal chelating and anti-inflammatory activity by that they can 
provide protection to normal tissue against radiation40.
Tinospora cordifolia, Emblica officinalis, Centella 
asiatica, Curcuma longa, Allium sativum, Piper longum, 
Mentha piperita, Aegle marmelos and Zingiber officinalis 
extracts also have been evaluated in different biological 
systems or animal models. They can be used as promising 
radioprotector either in their crude extract form or in the form 
of certain formulations41,42 but further studies are necessary.
3. rAdIoMItIGAtorS
Development of radiomitigator is also as important as 
radioprotector because it is required during unplanned and 
accidental radiation exposure. Radiomitigators are agents which 
are administered after radiation exposure to mitigate the effect 
of radiation43. Sulforaphane, Trichostatin A, Diallyl sulphide 
and epigallocatechin-3-gallate and other histone deacetylase 
inhibitors have shown effective radiomitigating activity44-
46. 5-androstenediol (5-AED), entolimod and recombinant 
human IL-12 are well known radioprotector at very advance 
stage of development but these all have also been evaluated as 
radiomitigator in mice and NHPs47,48.
3.1 5-androstenediol
It is a naturally occurring adrenal steroid hormone holding 
promise against hematological acute radiation syndrome 
as protector as well as mitigator. It stimulates recovery of 
various bone marrow lineages against radiation induced 
myelosuppression49. Neumune is an injectable suspension 
formulation of 5-AED and it has been tested on NHPs where 
it has been shown to mitigate hematopoietic effect induced by 
radiation and increase survivability50. It elevated the expression 
of NF-κB dependent granulocyte colony stimulating factor, 
induced the expression of bcl-2 and also decreased the 
persistence of DNA double strand breaks. 5-AED is suggested 
to mitigate radiation injuries by enhancing the level of 
expression of anti-apoptotic genes and growth factors50.
3.2 Histone deacetylase Inhibitors
Histone Deacetylase inhibitors (HDACi) are epigenetic 
modifiers involved in regulation of gene expression, 
differentiation, proliferation and apoptosis of cells. Some 
HDAC inhibitors have been approved by FDA for the 
treatment of various types of cancer like as vorinostat or 
SAHA. Moreover, HDAC inhibitors show effect in non-
oncologic diseases like asthma, arthritis, diabetes and muscular 
dystrophy. Some HDAC inhibitor has shown radiomitigation 
activity against radiation injury51. HDAC inhibitor increases 
histone acetylation thus increasing the accessibility of repair 
proteins to DNA and thereby enhancing DNA repair. HDAC 
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inhibitors were found to mitigate radiation induced lethality by 
stimulation of bone marrow stem cells52.
3.2.1 Sulforaphane
Sulforaphane (SFN) is an isothiocynate dietary 
supplement present in cruciferous vegetables like broccoli, 
cabbage and cauliflower and shows anticancer activity. SFN 
ameliorated radiation induced micronuclei frequency in 
human lymphocytes suggesting its antimutagenic effect due to 
enhanced repair activity. SFN acts by Nrf-2 Keap-1 pathway 
for its anticancer property53,54. SFN has been shown to inhibit 
histone deacetylase activity as well. SFN-cys competes for the 
binding site in HDAC thus it enhances histone acetylation level 
and increase anti apoptotic genes level55. Sulforaphane has the 
ability to mitigate the radiation induced genotoxicity and it can 
diminish both acute as well as late effects of radiation55.
3.2.2 Diallyl Sulphide
Diallyl sulphide (DAS) is a naturally occurring 
organosulphur present in garlic. It has histone deacetylase 
inhibitor activity besides antimutagenic, antimicrobial, hepato 
and reno protective activity51. DAS exhibits radioprotective 
activity in liver, intestinal mucosa and hematopoietic injury51, 
56-57. It enhances the bone marrow cellularity and spleen colony 
forming unit which further enhances the lymphocyte count. 
DAS has already been shown to enhance cellular antioxidant 
activity through Nrf-2 pathway under various stress condition.
 
3.2.3 Epigallocatechin-3-gallate
Green tea contains a polyphenol named as epigallocatechin-
3-gallate (EGCG) which shows high anti-oxidant and anti-
inflammatory activity. Administration of 100 µM concentration 
of EGCG shows protection against radiation induced DNA 
break, DNA damage and lipid peroxidation and membrane 
fluidity. The frequency of apoptosis in crypt cells is also 
reduced by the administration of EGCG. EGCG has widely 
studied for its anticancer activity and it can also alter the histone 
methylation and acetylation. EGCG is an inhibitor of DNMT1, 
a DNA methyl transferase enzyme and it also shows histone 
deacetylase inhibitor activity. EGCG enhanced the survival 
of mice and reduced the cytogenetic damage to bone marrow 
cells induced by radiation. EGCG has been shown to provide 
mitigation against radiation induced hematopoietic injury47,58.
4. tHErAPEutIcS 
A therapeutic is an agent which is given after the 
appearance of physical symptoms of radiation exposure. 
Clinical management for hematopoietic acute radiation 
syndrome is limited to supportive care59. Few agents have 
been tested as therapeutics and have been shown to improve 
survivability after irradiation.
4.1 Infusion of Hematopoietic Stem cells
Infusion of ex-vivo expanded murine hematopoietic 
stem (HSC) and progenitor cells (HSPC) into major 
histocompatibility complex (MHC) mismatched recipient 
mice exposed to a lethal dose of radiation led to rapid recovery 
of myeloid progenitor cells and resulted in improved survival. 
These HSCs and HSPCs are expanded in presence of notch 
ligand outside any biological system. Survival benefit was 
significant even after three days of lethal dose of irradiation. 
4.2 Growth Factors
It has already been reported that hematopoietic growth 
factors like IL-1, tumor necrosis factor (TNF), interferon-γ 
(IFN), GM-CSF and G-CSF when administered prior to 
radiation exposure render protection against hematopoietic 
syndrome60,61. They enhance survival when administered as 
therapeutics after radiation exposure also. Single injection of 
IL-1 promotes survival in a dose dependent manner and IFN-γ 
exhibits same effect62. Moreover, combination of growth 
factors has also been shown to be very effective against 
radiation. Combined administration of IL-3 and GM-CSF is 
more effective than administration of alone GM-CSF or IL-
363. Glucan, a macrophage activator when synergised with 
G-CSF enhanced survival and hematopoietic regeneration and 
recovers from myelosuppression64. Co-administeration of IL-6 
and IL-3 improves platelet recovery and survival65.
4.3 recombinant GcSF/ Filgrastim
Recombinant G-CSF provides protection when 
administered before radiation exposure but can also used as 
a therapeutic16,18. Administration of r-GCSF with supportive 
care as soon after radiation as possible has significant effect 
on lethality. It modulates the hematopoiesis and lessens the 
duration of neutropenia and thrombocytopenia. Thus, early 
and continuous administration of G-CSF with supportive 
care enhances recovery of myelopoiesis, neutrophil, platelets 
and survival66,67. It also recovers bone marrow, splenic and 
peripheral blood cellularity, splenic Granulocyte-Macrophage 
progenitor cells, multipotent HSCs and overall survival62,68.
4.4 recombinant Pegfilgrastim/neulasta
Pegfilgrastim, a leukocyte growth factor, has been studied 
as radioprotector extensively. But it also has the properties to be 
a therapeutic agent. It has been currently approved for treatment 
of chemotherapy induced myelosuppression. Filgrastim is the 
only LGF that has gone for efficacy assessment under animal 
efficacy rule to treat radiological and nuclear exposure injuries. 
Administration of Neulasta after 24 h and 8 days has increased 
survival in NHPs to 91.3 per cent against 47.8 per cent in 
the radiation alone group. It also decreased the intermediary 
time of thrombocytopenia and neutropenia and improved the 
recovery of neutrophil number in the animal exposed to a lethal 
dose of radiation leading to H-ARS69,70. Neutrophil recovery 
was significantly enhanced by administration of pegfilgrastim 
on day 1 and day 7 after radiation exposure compared to 
daily or single dose administration. It also enhances survival 
by mitigating cytopenia, thrombopenia, erythropenia and 
anemia71. It has also been reported that patients receiving 
pegfilgrastim had a lower incidence of febrile neutropenia than 
those received filgrastim72.
5. concluSIonS
From the present review it is apparent that there is 
requirement of more research in the field of mitigation and 
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therapeutics. To date, amifostin is the only drug that has 
been approved by USFDA for use as a protector but only 
under medical supervision. However, there are several 
radioprotective compounds which are either sowing successful 
results in pre-clinical studies or are in advanced stages of 
drug development. This is a good sign for the world that 
some degree of preparedness is expected soon in the area of 
radiation countermeasure which will be essential in the fight 
against terrorist threats involving nuclear or radiological 
material, nuclear power sector accidents, nuclear warfare and 
most importantly against the complications arising following 
radiotherapy. 
However, the process of any drug development so far 
is a very long, difficult, costly and low success story despite 
tremendous advancements in knowledge, approaches and 
technology. Especially, development of drugs against radiation 
induced morbidity and mortality becomes more complicated 
due to our inability to carry out human efficacy studies 
owing to ethical issues and hence the success rate is far low 
or beyond our ability to evaluate. Molecules or compounds, 
whether natural or synthetic, that are under investigation or 
development can only be expected to be useful but that cannot 
be ascertained. That of course poses another big issue related to 
post-marketing inspections and reporting of adverse reactions.
Considering all constrains it can easily be understood that 
the development of a radiation countermeasure agent, whether 
protector, mitigator or therapeutic is a very complicated task 
with rare success. Therefore, there is a need of constant and 
holistic efforts by more and more researchers with increasing 
will and funding from appropriate bodies.
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